熱門資訊> 正文
诺华获得FDA批准Fabhalta用于IgAN患者
2024-08-08 04:57
- Novartis (NYSE:NVS) has received FDA accelerated approval for its drug Fabhalta to be used in the reduction of proteinuria in adults with primary immunoglobulin A nephropathy, or IgAN, at risk of rapid disease progression, according to the agency’s website.
- According to the product's expanded label, continued approval for the indication could be contingent on a confirmatory clinical trial.
- Fabhalta is already approved for the treatment of adults with paroxysmal nocturnal hemoglobinuria, or PNH. The product was approved in December 2023.
Other approved drugs for IgAN include Travere Therapeutics’ (TVTX) Filspari and Calliditas Therapeutics’ (CALT) Tarpeyo.
More on Novartis
- Novartis: Another Beat, Another Raise
- Why Novartis Deserves Your Attention After Q2 2024 Results
- Novartis AG (NVS) Q2 2024 Earnings Call Transcript
- Novartis sues FDA for approving Entresto generic
- Novartis' Scemblix granted FDA Priority Review status for front-line CML
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
